Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax to Present Data on Obefazimod at Digestive Disease Week ® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical Anti-Fibrotic Models in Inflammatory Bowel Disease PARIS, France – April 22, 2026 – 10:05 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that nine scientific abstracts on obefazimod, its lead drug candidate for the treatment of moderately to severely active ulcerative colitis (UC), will be presented at the 2026 Digestive Disease Week (DDW) taking place May 2-5, 2026 in Chicago, IL. These presentations will highlight data from the Phase 3 ABTECT program, including efficacy, safety, and patient-reported outcomes, along with preclinical anti-fibrotic activity in two preclinical fibrosis models.